

Table 2. mRNA expression of prostatic proteins and AR in prostatic lobes

Treatment	SBP	SPI-KT3	PSP94	GRP78	Prdx6	Probasin	EAPA2	IgGBPLP	AR
VP									
control	315 ± 64.4	280 ± 85.7	12.4 ± 4.2	5.7 ± 0.36	1.5 ± 0.21				7.3 ± 1.24
TCDD 10	293 ± 131.2	495 ± 95.7	40.0 ± 11.9	7.6 ± 0.92	2.4 ± 0.38				8.6 ± 1.08
TCDD 100	322 ± 63.6	278 ± 44.1	65.7 ± 21.1*	8.3 ± 1.89	4.5 ± 0.79*				4.8 ± 0.27
TCDD 1000	450 ± 84.7	308 ± 46.5	110 ± 16.6**	7.1 ± 1.68	5.6 ± 1.0*				7.5 ± 0.71
DLP									
control			92.3 ± 20.2	11.2 ± 1.23	27.2 ± 4.7	7.8 ± 0.65	2.5 ± 0.44	0.80 ± 0.09	4.5 ± 0.96
TCDD 10			59.0 ± 24.3	9.5 ± 1.21	31.7 ± 1.93	9.1 ± 1.36	2.8 ± 0.44	2.2 ± 0.59	3.9 ± 0.45
TCDD 100			82.3 ± 20.7	8.9 ± 1.07	31.6 ± 3.02	8.5 ± 0.57	2.4 ± 0.29	2.7 ± 0.75*	3.5 ± 0.22
TCDD 1000			56.9 ± 15.9	7.3 ± 0.71	31.3 ± 2.46	7.9 ± 0.07	2.5 ± 0.28	3.3 ± 0.47*	3.2 ± 0.50
AP									
control				13.7 ± 3.23	38.1 ± 5.4	4.5 ± 0.66	3.4 ± 0.29	19.5 ± 1.95	3.6 ± 0.35
TCDD 10				18.0 ± 1.59	67.1 ± 4.1	5.8 ± 0.21	3.0 ± 0.33	27.8 ± 5.63	3.0 ± 0.31
TCDD 100				9.8 ± 0.91	40.9 ± 6.13	3.9 ± 0.52	3.0 ± 0.57	11.2 ± 1.90	1.9 ± 0.22
TCDD 1000				14.6 ± 1.90	73.6 ± 15.4	5.9 ± 0.75	3.3 ± 0.37	28.3 ± 6.19	2.1 ± 0.32

Mean ± S.E.M. (n = 5 or 6). Values are mRNA levels divided by beta actin mRNA levels (*p < 0.05 and **p < 0.01 vs. control). Male C57BL mice were treated with TCDD (10, 100, or 1,000 ng/kg body weight) at postnatal day (PND) 6 and sacrificed at PND42.

TCDD, especially when it is administered maternally (Bjerke and Peterson, 1994; Lin *et al.*, 2002b; Mably *et al.*, 1992; Theobald *et al.*, 2000). In the present study, we examined the effects of neonatal TCDD exposure on the expression of prostatic proteins and demonstrated that the administration of low doses of TCDD at PND6 resulted in the abnormal hyper-expression of PSP94, Prdx6, and IgGBPLP mRNAs at PND42 in C57BL mice. Although the expression of all the prostatic proteins is regulated by androgen as we previously reported (Fujimoto *et al.*, 2006), only three of them were hyper-expressed, that may suggest the neonatal TCDD did not change androgen levels.

There is a difference in the acute lethality of TCDD among different mouse strains, with an LD50 of approximately 100 µg/kg bw in the "sensitive" C57BL/6J strain, while it is more than 3 mg/kg bw in "non-sensitive" DBA mice (Weber *et al.*, 1995). The C57BL/6J strain demonstrated a higher susceptibility to developmental disruption of the male reproductive system by maternal exposure to TCDD (Theobald *et al.*, 2000). In the rat, there are also great differences in the acute lethality of TCDD among strains, but the effects of TCDD on the development of the prostate seem to be similar among strains (Simanainen *et al.*, 2004).

The development of the prostatic gland begins with the formation of epithelial buds from the urogenital sinus at gestational day (GD) 17; these then develop into the prostatic main ducts (Cunha *et al.*, 1987). After birth, extensive branching and growth from the duct takes place to generate the mature prostate. Approximately 70-80% of ductal tips and 50-70% of branching points are formed during the first 15 days after birth, while ductal branching continues throughout adolescence (Sugimura *et al.*, 1986). Vulnerability to the effects of TCDD on the development of the prostate has been studied extensively in C57BL/6J mice, in which the oral administration of 5 µg/kg bw TCDD on GD 13 reduced VP weight by 84%. Lactational exposure alone to TCDD also significantly suppressed VP weight by 41%. For the DLP and AP, the effects were less severe, with lactational exposure alone reducing their weight by approximately 20%, while in utero exposure caused a 50% reduction (Lin *et al.*, 2002b). Our data may suggest that the prostate at PND 6 may be less susceptible for TCDD suppressing the prostatic growth but sensitive for the functional alteration. Further studies are needed to understand what timing of TCDD exposure is critical to lead to changes in expression of prostatic proteins.

Although prostatic secreted proteins are found in the seminal fluid, it is not clear what their physiological roles are. PSP94 is one of the major proteins secreted by the

human prostate and is also abundantly secreted by the rodent prostate. PSP94 is known to be expressed mainly in the VP and DLP in mice. This protein may function as an immunoglobulin-binding protein and is involved in the regulation of the immune response in the female reproductive tract (Kamada *et al.*, 1998). It also functions as an inhibitor of sperm motility and of the acrosome reaction. IgGBPLP is abundantly expressed in the DLP and AP and may have a similar function to PSP94 (Kumar *et al.*, 2010). Prdx6 is an antioxidant enzyme that reduces peroxide and alkyl hydroperoxide to water and alcohol, respectively, and it may have a seminal plasma antioxidant capability (Wang *et al.*, 2004). The changes in the composition of prostatic secretions caused by the hyper-expression of these proteins might eventually affect normal fertility.

The present study demonstrated that neonatal exposure to low levels of TCDD changes the normal expression pattern of prostatic protein mRNAs later on in life, although it is not known whether these changes are physiologically detrimental. Previous studies have emphasized the suppressive effects of TCDD on the size of the prostate. However, the present study suggested that exposure to low doses of TCDD in the neonatal period may affect the expression patterns of prostate proteins.

ACKNOWLEDGMENTS

This research was partially supported by a Grant-in-Aid (H19-Kagaku-Ippan-003) from the Ministry of Health, Labour and Welfare, Japan.

REFERENCES

- Bjerke, D.L. and Peterson, R.E. (1994): Reproductive toxicity of 2,3,7,8-tetrachlorodibenzo-p-dioxin in male rats: different effects of in utero versus lactational exposure. *Toxicol. Appl. Pharmacol.*, **127**, 241-249.
- Cunha, G.R., Donjacour, A.A., Cooke, P.S., Mee, S., Bigsby, R.M., Higgins, S.J. and Sugimura, Y. (1987): The endocrinology and developmental biology of the prostate. *Endoc. Rev.*, **8**, 338-362.
- Fujimoto, N., Akimoto, Y., Suzuki, T., Kitamura, S. and Ohta, S. (2006): Identification of prostatic-secreted proteins in mice by mass spectrometric analysis and evaluation of lobe-specific and androgen-dependent mRNA expression. *J. Endo.*, **190**, 793-803.
- Kamada, M., Mori, H., Maeda, N., Yamamoto, S., Kunimi, K., Takikawa, M., Maegawa, M., Aono, T., Futaki, S. and Koide, S.S. (1998): beta-Microseminoprotein/prostatic secretory protein is a member of immunoglobulin binding factor family. *Biochem. Biophys. Acta*, **1388**, 101-110.
- Ko, K., Theobald, H.M. and Moore, R.W. and Peterson, R.E. (2004): Evidence that inhibited prostatic epithelial bud formation in 2,3,7,8-tetrachlorodibenzo-p-dioxin-exposed C57BL/6J fetal mice is not due to interruption of androgen signaling in the urogenital sinus. *Toxic. Sci.*, **79**, 360-369.

Effects of neonatal TCDD on prostatic protein mRNA

- Kumar, A., Jagtap, D.D., Mahale, S.D. and Kumar, M. (2010): Crystal structure of prostate secretory protein PSP94 shows an edge-to-edge association of two monomers to form a homodimer. *J. Mol. Biol.*, **397**, 947-956.
- Lin, T. m., Ko, K., Moore, R.W., Simanainen, U., Oberley, T.D. and Peterson, R.E. (2002a): Effects of aryl hydrocarbon receptor null mutation and in utero and lactational 2,3,7,8-tetrachlorodibenzo-p-dioxin exposure on prostate and seminal vesicle development in C57BL/6 mice. *Toxic. Sci.*, **68**, 479-487.
- Lin, T.M., Simanainen, U., Moore, R.W. and Peterson, R.E. (2002b): Critical windows of vulnerability for effects of 2,3,7,8-tetrachlorodibenzo-p-dioxin on prostate and seminal vesicle development in C57BL/6 mice. *Toxic. Sci.*, **69**, 202-209.
- Mably, T.A., Moore, R.W. and Peterson, R.E. (1992): In utero and lactational exposure of male rats to 2,3,7,8-tetrachlorodibenzo-p-dioxin. I. Effects on androgenic status. *Toxicol. Appl. Pharmacol.*, **114**, 97-107.
- Ohsako, S., Miyabara, Y., Nishimura, N., Kurosawa, S., Sakaue, M., Ishimura, R., Sato, M., Takeda, K., Aoki, Y., Sone, H., Tohyama, C. and Yonemoto, J. (2001): Maternal exposure to a low dose of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) suppressed the development of reproductive organs of male rats: dose-dependent increase of mRNA levels of 5 α -reductase type 2 in contrast to decrease of androgen receptor in the pubertal ventral prostate. *Toxicol. Sci.*, **60**, 132-143.
- Roman, B.L. and Peterson, R.E. (1998): In utero and lactational exposure of the male rat to 2,3,7,8-tetrachlorodibenzo-p-dioxin impairs prostate development. I. Effects on gene expression. *Toxicol. Appl. Pharmacol.*, **150**, 240-253.
- Simanainen, U., Adamsson, A., Tuomisto, J.T., Miettinen, H. M., Toppari, J., Tuomisto, J. and Viluksela, M. (2004): Adult 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) exposure and effects on male reproductive organs in three differentially TCDD-susceptible rat lines. *Toxic. Sci.*, **81**, 401-407.
- Sugimura, Y., Cunha, G.R. and Donjacour, A.A. (1986): Morphogenesis of ductal networks in the mouse prostate. *Biol. Reprod.*, **34**, 961-971.
- Theobald, H.M., Roman, B.L., Lin, T.M., Ohtani, S., Chen, S.W. and Peterson, R.E. (2000): 2,3,7,8-Tetrachlorodibenzo-P-Dioxin Inhibits Luminal Cell Differentiation and Androgen Responsiveness of the Ventral Prostate Without Inhibiting Prostatic 5 α -Dihydrotestosterone Formation or Testicular Androgen Production in Rat Offspring. *Toxic. Sci.*, **58**, 324-338.
- Wang, M.H., Grossmann, M.E. and Young, C.Y.F. (2004): Forced expression of heat-shock protein 70 increases the secretion of Hsp70 and provides protection against tumour growth. *Br. J. Cancer*, **90**, 926-931.
- Weber, L.W., Lebofsky, M., Stahl, B.U., Smith, S. and Rozman, K.K. (1995): Correlation between toxicity and effects on intermediary metabolism in 2,3,7,8-tetrachlorodibenzo-p-dioxin-treated male C57BL/6J and DBA/2J mice. *Toxicol. Appl. Pharmacol.*, **131**, 155-162.



Autoimmune regulator, *Aire*, is a novel regulator of chondrocyte differentiation



Yuan Si^a, Kazuki Inoue^{a,b,c}, Katsuhide Igarashi^d, Jun Kanno^d, Yuuki Imai^{a,c,*}

^aLaboratory of Epigenetic Skeletal Diseases, Institute of Molecular and Cellular Biosciences, The University of Tokyo, Tokyo, Japan

^bDepartment of Biological Resources, Integrated Center for Science, Ehime University, Ehime, Japan

^cDivision of Integrative Pathophysiology, Proteo-Science Center, Ehime University, Ehime, Japan

^dDivision of Cellular & Molecular Toxicology, Biological Safety Research Center, National Institute of Health Sciences, Tokyo, Japan

ARTICLE INFO

Article history:

Received 27 June 2013

Available online 11 July 2013

Keywords:

Chondrocyte differentiation

Aire

BMP2

Histone modification

ABSTRACT

Chondrocyte differentiation is controlled by various regulators, such as Sox9 and Runx2, but the process is complex. To further understand the precise underlying molecular mechanisms of chondrocyte differentiation, we aimed to identify a novel regulatory factor of chondrocyte differentiation using gene expression profiles of micromass-cultured chondrocytes at different differentiation stages. From the results of microarray analysis, the autoimmune regulator, *Aire*, was identified as a novel regulator. *Aire* stable knockdown cells, and primary cultured chondrocytes obtained from *Aire*^{-/-} mice, showed reduced mRNA expression levels of chondrocyte-related genes. Over-expression of *Aire* induced the early stages of chondrocyte differentiation by facilitating expression of *Bmp2*. A ChIP assay revealed that *Aire* was recruited on an *Aire* binding site (T box) in the *Bmp2* promoter region in the early stages of chondrocyte differentiation and histone methylation was modified. These results suggest that *Aire* can facilitate early chondrocyte differentiation by expression of *Bmp2* through altering the histone modification status of the promoter region of *Bmp2*.

Taken together, *Aire* might play a role as an active regulator of chondrocyte differentiation, which leads to new insights into the regulatory mechanisms of chondrocyte differentiation.

© 2013 Elsevier Inc. All rights reserved.

1. Introduction

Chondrocyte differentiation is a process that establishes skeletal morphology during embryonic development as well as longitudinal growth after birth. Chondrocytes are differentiated from mesenchymal stem cells (MSCs), with subsequent differentiation into proliferative chondrocytes and then into hypertrophic chondrocyte [1,2]. This sequential differentiation is regulated by various factors such as SRY-box containing gene 9 (Sox9), Indian hedgehog (Ihh), and parathyroid hormone-related protein (PTHrP) [1]. In early chondrocyte differentiation, Sox9, which is a crucial transcription factor mediated by Ihh/PTHrP and bone morphogenetic protein (BMP) signaling [3], regulates cartilage formation via up-regulation of chondrocyte-specific genes such as *Col2a1* by cooperating with various proteins [4–6]. During the maturation stage, the expression of Sox9 can be down-regulated by RelA (a member of the NF-κB family). Subsequently, runt-related transcription factor

2 (Runx2) can induce differentiation into hypertrophic chondrocytes, which have high expression of *Col10a1* [7].

The mutation of the gene locus of these known factors can cause severe metaphyseal and/or epiphyseal dysplasias and chondrodysplasia [8–10]. However, the genes responsible for various osteochondrodysplasias and chondrocyte-related diseases remain elusive. It is necessary to understand the molecular mechanisms underlying chondrocyte differentiation for investigation into novel approaches to treat cartilage-related diseases. Consequently, identification of novel factors driving the process of chondrocyte differentiation, especially those related to epigenetic regulation, should be considered.

Epigenetic regulation is a mechanism that can control chromatin dynamics followed by transcriptional activation and repression [11]. Epigenetic regulations are mediated through reversible chemical modifications on DNA and histone proteins, and their recognition by various enzymes and nuclear proteins [12]. It has been reported that these epigenetic regulators play a significant role *in vivo* as well as *in vitro* [13–15]. However, epigenetic regulations in chondrocyte differentiation are still largely unknown. Thus, the purpose of this study was to identify novel transcription and/or epigenetic factors in chondrocyte differentiation in order to investigate the underlying molecular

* Corresponding author. Address: Division of Integrative Pathophysiology, Proteo-Science Center, Ehime University, Shitsugawa, Toon, Ehime 791-0295 Japan. Tel.: +81 89 960 5925; fax: +81 89 960 5953.

E-mail address: y-imai@m.ehime-u.ac.jp (Y. Imai).

mechanisms using an *in vitro* micromass culture system and gene expression microarrays.

2. Materials and methods

2.1. Animals

C57BL/6j mice were purchased from CLEA Japan (Tokyo, Japan) and *Aire*^{-/-} mice were kindly provided from Dr. Mitsuru Matsumoto at Tokushima University, Japan [16]. All animals were maintained according to a protocol approved by the Animal Care and Use Committee of the University of Tokyo.

2.2. Chondrocytic cell culture

C3H10T1/2 cells were maintained in Dulbecco's Modified Eagle Medium (DMEM, Wako, Osaka, Japan) containing 10% fetal bovine serum (FBS, Nichirei Biosciences, Tokyo, Japan) and antibiotic-antimycotic (Gibco, USA) at 37 °C in an atmosphere of 5% CO₂. To induce chondrocyte differentiation, micromass-cultured C3H10T1/2 cells were treated with 100 ng/ml of recombinant human BMP2 (Osteopharma, Osaka, Japan) as previously reported [17]. Medium was changed every 2 days.

The early stage chondrogenic cell line, ATDC5, was maintained in DMEM/F12 (Gibco) with 5% FBS and antibiotic-antimycotic.

Primary chondrocytes were isolated from articular cartilage of postpartum mice at day 6 as previously reported [18]. The isolated chondrocytes were cultured at a density of 10⁴ cells/well in a 24-well plate with 1.5 ml/well of DMEM (high glucose) with antibiotic-antimycotic and 10% FBS under sterile conditions in an atmosphere of 5% CO₂ at 37 °C. The culture medium was changed every 2 days. Cells were harvested at day 7 for RT-PCR.

2.3. Gene expression microarray analysis

Micromass-cultured cells were harvested at days 0, 5, 9 and 15, and gene expression microarrays were performed as described previously [19,20]. A heat map was generated with Multi Experiment Viewer software. Data were clustered and analyzed with DAVID bioinformatics database (<http://david.abcc.ncifcrf.gov/>) [21].

2.4. Real-time RT-PCR

Total RNA was extracted with Trizol (Invitrogen, USA) and was subsequently treated with DNase I (Takara Biolnc., Otsu, Japan). First-strand cDNA was synthesized from total RNA using PrimeScript RT Master Mix (Takara Bio Inc.) and subjected to real-time RT-PCR using SYBR Premix Ex Tag II (Takara Bio Inc.) with Thermal Cycler Dice (Takara Bio Inc.) according to the manufacturer's instructions. Primers were purchased from Operon Biotechnologies (Tokyo, Japan) and the sequences of the primer sets are shown in Supplementary Table 1.

2.5. Immunohistochemistry (IHC)

Immunohistochemistry was performed as previously described [19]. Briefly, paraffin sections of decalcified tibiae of 9-week-old C57BL/6 mice were incubated overnight with primary antibodies (anti-Aire, LS-C29969, Lifespan, 1:1000 diluted by 2% goat serum in PBST) and then treated with a biotinylated secondary antibody (Vector Laboratories) and an avidin-biotin peroxidase complex (ABC Vectastain Kit, Vector). Diaminobenzidine tetrahydrochloride (Sigma) was the chromogen. Negative controls were prepared by omitting the primary antibody and replacing it with non-immune serum at the same dilution.

2.6. Establishment of Aire stable knockdown cell line

Knockdown experiments were performed as previously described [13]. Briefly, oligonucleotide sequences for short hairpin RNA (shRNA) targeting *Aire*, *Sox9* and *LacZ* were designed via BLOCK-iT™ RNAi designer (Invitrogen) and cloned into the pSUPER.reto.puro vector. Each vector was transfected into the Platinum-E cell line with lipofectamine2000 (Invitrogen). After 2 days, retrovirus was produced and infected into C3H10T1/2 cells with 10 µg/ml polybrene. 24 h later, cells were passaged and treated with puromycin (5 µg/ml) to select the infected cells. Culture medium was changed every 2 days. After 7 days, the stable knockdown cells were produced and the efficiency of knockdown was determined by real-time RT-PCR.

2.7. Luciferase reporter assay

A reporter plasmid was constructed using pGL3 (Promega) and 2 kb upstream from the transcriptional start site of the *Bmp2* gene. A reporter assay for the detection of transcriptional activity was performed with the Dual-Luciferase Reporter assay system (Promega). Approximately 80% confluent ATDC5 cells were transfected with *Bmp2* promoter-luciferase reporter plasmids with expression vectors of *Aire*. For evaluating transfection efficiency, the renilla-luciferase gene derived from the CMV promoter was used. Transfection was performed with Superfect transfection reagent (QIAGEN) according to the manufacturer's instructions. A dual luciferase assay was performed according to the manufacturer's instructions. In each experiment, firefly luciferase activity was normalized to renilla luciferase activity.

2.8. Chromatin immunoprecipitation (ChIP) assay

A ChIP assay was performed as described [13,22] with anti-Aire (ab13573, Abcam), anti-H3K4me2 (ab7766, Abcam) and normal goat or rabbit IgG as a control. Primer sets used for PCR were as follows: *Aire* binding T box site forward primer; 5'-CAAACAGAAGC GTTGGCTCAC-3', reverse primer; 5'-TGGCCTCTGAGTCCCTCATT-3' and negative control site (about -5000 bp) forward primer; 5'-TCACTGGTACTTATGGCTGTGATG-3', reverse primer; 5'-TCTGTGTT CCTGCTCTGCT-3'.

2.9. Statistical analysis

We used one-way analysis of variance (ANOVA) to initially determine whether an overall statistically significant change existed before using Tukey's *post hoc* test and a two-tailed Student's *t* test to analyze the differences between two groups. For all graphs, data are represented as the mean ± S.D. Statistical significance was accepted at $p < 0.05$.

3. Results

3.1. Identification of the novel transcriptional factor, *Aire*, in chondrocyte differentiation

To identify novel transcriptional and/or epigenetic regulators in chondrocyte differentiation, micromass-cultured C3H10T1/2 cells were analyzed to establish chondrocyte differentiation *in vitro*. RT-PCR showed that *Col2a1* was highly expressed at day 5 and subsequently decreased, whereas the expression peak of *Col10a1* was detected at day 9 compared with other time points (Fig. 1A). This suggested that the micromass-cultured cells at days 0, 5 and 9 could be considered as MSCs, proliferative chondrocytes and hypertrophic chondrocytes, respectively.




Fig. 1. Aire was identified as a novel transcriptional factor in chondrocyte differentiation. (A) Expression levels of *Col2a1* and *Col10a1* of micromass-cultured C3H10T1/2 cells treated with BMP2 for 0, 5, 9 and 15 days as determined by real-time RT-PCR and normalized to *Gapdh*. (B) A heat map of differentially expressed genes comparing day 0 and day 5. Genes with more than a 5-fold increase or 0.2-fold decrease as generated via Multi Experiment viewer software. (C) Expression levels of the genes categorized as "transcription" in the microarray. (D) Validation of microarray data by real-time RT-PCR and normalized to *Gapdh*. Data are presented as mean \pm S.D. * indicates $p < 0.05$.

Based on the established pattern of chondrocyte differentiation, data from gene expression microarray showed a 5-fold significant difference of 785 genes (up-regulated: 365, down-regulated: 420) that were differentially expressed between day 0 and day 5 (Fig. 1B). All of them were clustered and analyzed based on the keyword "transcriptional factors" via the DAVID bioinformatics

database and 14 factors were identified as possible candidates (Fig. 1C). After validation using real-time RT-PCR, the expression levels of Aire at day 5 were confirmed as the most significant increase compared to that at day 0 (Fig. 1D). Thus, Aire was suggested to be a novel transcription regulatory factor in chondrocyte differentiation.

3.2. Aire may activate the early stages of chondrocyte differentiation

To determine the expression of Aire during chondrocyte differentiation *in vitro* and *in vivo*, real-time RT-PCR and IHC was performed. Aire was notably expressed after day 5 of chondrocyte differentiation (Fig. 2A) and Aire positively-stained cells were predominantly localized in the proliferative zone as well as the hypertrophic zone, but not in the resting zone of mouse tibiae (Fig. 2B). Therefore, the change in expression profile of Aire occurred in the early stages of chondrocyte differentiation.

Next, to determine whether Aire affected chondrocyte differentiation, we knocked down Aire in micromass-cultured C3H10T1/2 cells and harvested cells at days 0, 5 and 9 after BMP2 treatment. The knockdown efficiency of Aire-shRNA (shAire) was confirmed by RT-PCR compared with LacZ-shRNA (shLacZ)-infected cells (Fig. 2C). The expression of chondrocyte differentiation marker genes (*Col2a1* and *Col10a1*) was decreased by Aire knockdown (Fig. 2C). These data suggested that Aire might be regarded as an activator of chondrocyte differentiation.

3.3. Aire may up-regulate Bmp2 expression

Our results suggested that Aire may up-regulate chondrocyte-related genes and promote the early stages of chondrocyte differentiation. However, the target genes of Aire in chondrocyte differentiation are unknown. It has been documented that the expression of *Bmp2*, the well-known chondrocyte differentiation inducer, was repressed in *Aire*^{-/-} thymic epithelial cells [10]. Thus, it was hypothesized that Aire might activate chondrocyte-related genes via regulation of *Bmp2* expression.

As micromass-cultured C3H10T1/2 cells are unable to differentiate into chondrocytes without the induction of BMP2 we knocked down Aire in ATDC5 cells to determine the effect of Aire on

endogenous *Bmp2*. At day 2, ATDC5 cells were harvested and the RNA was extracted to analyze the mRNA expression of *Bmp2*. *Bmp2* expression was significantly decreased in Aire knockdown ATDC5 cells (Fig. 3A). In addition, this result was confirmed in primary cultured chondrocytes obtained from *Aire*^{-/-} mice and wild-type littermates (Fig. 3B). These results indicated that Aire might regulate expression of *Bmp2* in the early stages of chondrocyte differentiation.

Furthermore, to determine whether Aire could directly regulate transcription of *Bmp2* in early stages of chondrocyte differentiation, transcriptional activity of Aire was examined by a luciferase reporter assay using the *Bmp2* promoter. The results showed that Aire could significantly increase *Bmp2* promoter activity in ATDC5 cells (Fig. 3C). In addition, overexpression of Aire could induce *Bmp2* expression as well as *Col2a1* and *Sox9* expression in C3H10T1/2 cells without BMP2 treatment (Fig. 3D). Taken together, these results indicate that Aire may facilitate chondrocyte differentiation via transcriptional activation of *Bmp2* expression.

3.4. Aire bound to the Bmp2 promoter with alteration of H3K4me2 modification

Aire consensus-binding motifs have been identified as the ATTGGTTA (G box) and TTATTA (T box) [23]. The T box motif exists in the *Bmp2* promoter (Fig. 4A: -1503 to -1497 bp). To determine whether Aire bound to the endogenous *Bmp2* promoter, we performed a ChIP-qPCR assay using shAire C3H10T1/2 cells treated with BMP2 for 1 or 3 days. Aire binding was confirmed at the T box site, but not at the negative control site, in the *Bmp2* promoter (Fig. 4B). As expected, the recruitment of Aire was significantly decreased in shAire cells. To further understand the molecular mechanisms of Aire on the *Bmp2* promoter in chondrocyte differentiation, we investigated histone H3K4 modification, especially




Fig. 2. Knockdown of Aire decreased the expression of chondrocyte-related genes. (A) Expression levels of Aire of micromass-cultured C3H10T1/2 cells treated with BMP2 for 0, 5 and 9 days as determined by real-time RT-PCR and normalized to *Gapdh*. (B) Immunohistochemistry of Aire in the proximal tibial growth plate. Immuno-positive cells stained in brown were localized in the proliferating zone and the hypertrophic zone (Arrow heads). The scale bar indicates 50 μ m. (C) Expression levels of Aire, *Col2a1* and *Col10a1* of micromass-cultured C3H10T1/2 cells treated with shAire or shLacZ (negative control) and treated with BMP2 for 0, 5 and 9 days, as determined by real-time RT-PCR and normalized to *Gapdh*. Data are presented as mean \pm S.D. * indicates $p < 0.05$. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)




Fig. 3. Aire can facilitate chondrocyte differentiation by up-regulating *Bmp2* expression. (A) The expression of *Bmp2* was down-regulated by shAire in ATDC5 cells, as determined by real-time RT-PCR. (B) The expression levels of *Bmp2* in primary cultured chondrocytes obtained from *Aire*^{-/-} mice was decreased compared to that of *Aire*^{+/+} littermates, as determined by real-time RT-PCR. Data are presented as mean \pm S.D. * indicates $p < 0.05$. (C) A luciferase assay was performed in ATDC5 cells transfected with the luciferase reporter vector (pGL3) including 2 kb of the *Bmp2* promoter and Aire expression vector (pcDNA3.1-Flag-Aire vector). Data are presented as mean \pm S.D. * indicates $p < 0.05$ when compared to a mock transfection. (D) Expression levels of *Aire*, *Col2a1* and *Sox9* in micromass-cultured C3H10T1/2 cells without BMP2 treatment, as determined by real-time RT-PCR and normalized to *Gapdh*. Data are presented as mean \pm S.D. * indicates $p < 0.05$.

the di-methylation of H3K4 since Aire contains a PHD zinc finger, which can recognize hypomethylated H3K4 [24]. As a result of a ChIP-qPCR assay, H3K4me2 was detected in the T box in the *Bmp2* promoter, and the modification levels were increased during chondrocyte differentiation. When Aire expression was knocked down, H3K4me2 levels at the T box site were decreased (Fig. 4C). Taken together, Aire may directly bind to the consensus Aire binding motif in the *Bmp2* promoter to regulate its expression through alteration of histone H3K4 methylation.

4. Discussion

In this study, we used gene expression microarrays to identify novel transcriptional and/or epigenetic factors in chondrocyte differentiation, which may give insight into the mechanism of chondrocyte differentiation. The microarray data showed that several differentially expressed genes exist during chondrocyte differentiation. In proliferative chondrocyte differentiation, the expression of Aire was significantly up-regulated. Analyses of Aire stable knockdown cells and *Aire*^{-/-} primary cultured cells revealed that Aire may facilitate early stages of chondrocyte differentiation.




Fig. 4. Aire bound to the *Bmp2* promoter regulates *Bmp2* expression through histone H3K4 modification. (A) Schematic models of a ChIP assay for the T box and negative control sites (N.C.) in the *Bmp2* promoter region. A ChIP assay was performed using anti-Aire antibody (B) and anti-H3K4me2 antibody (C) for DNA extracted from micromass-cultured C3H10T1/2 cells treated with shAire or shLacZ (negative control) and BMP2 for 1 and 3 days. Data were normalized by % input and are represented as mean \pm S.D. * indicates $p < 0.05$.

BMP2 a member of the transforming growth factor- β superfamily, plays a key role in inducing differentiation of MSCs into chondrocytes to form cartilage tissue via the BMP/Smad signaling pathway [25,26]. BMP2 is regulated by Gli2 in the sonic hedgehog signaling pathway. In this pathway, PI3-kinase/insulin-like growth factor can induce the expression of Gli2 [27]. Moreover, it has been documented that Aire is an active insulin regulator in thymus cells and *Bmp2* was repressed in *Aire*^{-/-} thymic epithelial cells [28]. Based on this knowledge, we characterized the function of Aire on *Bmp2* expression in chondrocytes and found that Aire may play a role in the regulation of *Bmp2* expression through histone modification. These results were supported by previous reports, which suggested that the PHD1 domain of Aire can bind to hypomethylated H3K4 to concentrate Aire in binding regions and then activate the expression of target genes in mammary epithelial cells (MECs) [29].

Aire consists of a PHD zinc finger, but no significant domains harboring methyltransferase activities. However, a ChIP assay revealed that knockdown of Aire could decrease H3K4me2 levels at the T box site in the *Bmp2* promoter region. This alteration can be caused by histone modifiers, which interact with Aire on chromatin. It has been demonstrated that the PHD zinc finger of Aire can recognize hypomethylated histone H3 N-terminal tails to recruit transcriptional co-regulators including histone modifiers [24]. Identification of components of the Aire complex by biochemical purification may lead to comprehension of the precise molecular

mechanisms in the regulation of *Bmp2* expression by Aire during early chondrocyte differentiation.

Aire^{-/-} mice did not exhibit significant abnormal phenotypes in skeletal morphology [28]. However, patients with mutations at the *AIRE* gene locus suffer from autoimmune polyendocrinopathy candidiasis ectodermal dystrophy (APECED) and some of them show reversible metaphyseal dysplasia (RMD) with notable progressive growth and abnormal endochondral ossification in adolescents [30]. *Cst10*^{-/-} mice developed and grew normally but showed abnormal phenotypes in formation of osteoarthritic osteophytes, age-related ectopic ossification and healing of bone fractures [31]. Our current study and previous reports suggest that Aire might play an important role in chondrocyte differentiation during pathological conditions such as fracture healing or osteoarthritis development. Induction of skeletal diseases into *Aire*^{-/-} mice will help to further understand the precise roles of Aire in chondrocyte differentiation in pathological conditions.

Taken together, we have identified a novel regulatory factor in chondrocyte differentiation, Aire, which can modify *Bmp2* expression though alteration of the epigenetic status of the *Bmp2* promoter region. This investigation may open the window for the development of therapeutic strategies against diseases related to chondrocyte differentiation, such as osteoarthritis or fracture healing.

Acknowledgments

We would like to thank Prof. Mitsuru Matsumoto at Tokushima University, Japan for providing us the *Aire* knockout mice and Osteopharma for providing us rhBMP2. We also thank Ms. Noriko Moriyama at National Institute of Health Sciences, Tokyo, Japan, for her technical support (microarray). This work was supported by JSPS KAKENHI Grant Number 23689066 to Y.I.

Appendix A. Supplementary data

Supplementary data associated with this article can be found, in the online version, at <http://dx.doi.org/10.1016/j.bbrc.2013.07.001>.

References

- [1] H.M. Kronenberg, Developmental regulation of the growth plate, *Nature* 423 (2003) 332–336.
- [2] O. Nilsson, D. Chrysis, I. Pajulo, A. Boman, M. Holst, J. Rubinstein, E.M. Ritzen, L. Savendahl, Localization of estrogen receptors-alpha and -beta and androgen receptor in the human growth plate at different pubertal stages, *J. Endocrinol.* 177 (2003) 319–326.
- [3] J. Kramer, C. Hegert, K. Guan, A.M. Wobus, P.K. Muller, J. Rohwedel, Embryonic stem cell-derived chondrogenic differentiation in vitro: activation by BMP-2 and BMP-4, *Mech. Dev.* 92 (2000) 193–205.
- [4] K. Hata, R. Nishimura, S. Muramatsu, A. Matsuda, T. Matsubara, K. Amano, F. Ikeda, V.R. Harley, T. Yoneda, Paraspeckle protein p54nrb links Sox9-mediated transcription with RNA processing during chondrogenesis in mice, *J. Clin. Invest.* 118 (2008) 3098–3108.
- [5] K. Amano, K. Hata, S. Muramatsu, M. Wakabayashi, Y. Takigawa, K. Ono, M. Nakanishi, R. Takashima, M. Kogo, A. Matsuda, R. Nishimura, T. Yoneda, Arid5a cooperates with Sox9 to stimulate chondrocyte-specific transcription, *Mol. Biol. Cell.* 22 (2011) 1300–1311.
- [6] Y. Takigawa, K. Hata, S. Muramatsu, K. Amano, K. Ono, M. Wakabayashi, A. Matsuda, K. Takada, R. Nishimura, T. Yoneda, The transcription factor Znf219 regulates chondrocyte differentiation by assembling a transcription factory with Sox9, *J. Cell Sci.* 123 (2010) 3780–3788.
- [7] M. Ushita, T. Saito, T. Ikeda, F. Yano, A. Higashikawa, N. Ogata, U. Chung, K. Nakamura, H. Kawaguchi, Transcriptional induction of SOX9 by NF- κ B family member RelA in chondrogenic cells, *Osteoarthritis Cartilage* 17 (2009) 1065–1075.
- [8] J. Spranger, A. Winterpacht, B. Zabel, The type II collagenopathies: a spectrum of chondrodysplasias, *Eur. J. Pediatr.* 153 (1994) 56–65.
- [9] T. Wagner, J. Wirth, J. Meyer, B. Zabel, M. Held, J. Zimmer, J. Pasantes, F.D. Bricarelli, J. Keutel, E. Huster, U. Wolf, N. Tommerup, W. Schempp, G. Scherer, Autosomal sex reversal and campomelic dysplasia are caused by mutations in and around the SRX-related gene SOX9, *Cell* 79 (1994) 1111–1120.
- [10] J.W. Foster, M.A. Dominguez-Steglich, S. Guioli, C. Kwok, P.A. Weller, M. Stevanovic, J. Weissenbach, S. Mansour, I.D. Young, P.N. Goodfellow, et al., Campomelic dysplasia and autosomal sex reversal caused by mutations in an SRX-related gene, *Nature* 372 (1994) 525–530.
- [11] M.G. Rosenfeld, V.V. Lunyak, C.K. Glass, Sensors and signals: a coactivator/corepressor/epigenetic code for integrating signal-dependent programs of transcriptional response, *Genes Dev.* 20 (2006) 1405–1428.
- [12] R.K. Prinjha, J. Witherington, K. Lee, Place your BETs: the therapeutic potential of bromodomains, *Trends Pharmacol. Sci.* 33 (2012) 146–153.
- [13] Y. Okuno, F. Ohtake, K. Igarashi, J. Kanno, T. Matsumoto, I. Takada, S. Kato, Y. Imai, Epigenetic regulation of adipogenesis by PHF2 histone demethylase, *Diabetes* 62 (2013) 1426–1434.
- [14] Y. Okada, K. Yamagata, K. Hong, T. Wakayama, Y. Zhang, A role for the elongator complex in zygotic paternal genome demethylation, *Nature* 463 (2010) 554–558.
- [15] Y. Okada, G. Scott, M.K. Ray, Y. Mishina, Y. Zhang, Histone demethylase JHDM2A is critical for Tnp1 and Prm1 transcription and spermatogenesis, *Nature* 450 (2007) 119–123.
- [16] N. Kuroda, T. Mitani, N. Takeda, N. Ishimaru, R. Arakaki, Y. Hayashi, Y. Bando, K. Izumi, T. Takahashi, T. Nomura, S. Sakaguchi, T. Ueno, Y. Takahama, D. Uchida, S. Sun, F. Kajiwara, Y. Mouri, H. Han, A. Matsushima, G. Yamada, M. Matsumoto, Development of autoimmunity against transcriptionally unrepressed target antigen in the thymus of Aire-deficient mice, *J. Immunol.* 174 (2005) 1862–1870.
- [17] A.E. Denker, A.R. Haas, S.B. Nicoll, R.S. Tuan, Chondrogenic differentiation of murine C3H10T1/2 multipotential mesenchymal cells: i. stimulation by bone morphogenetic protein-2 in high-density micromass cultures, *Differentiation* 64 (1999) 67–76.
- [18] M.C. Louie, H.Q. Yang, A.H. Ma, W. Xu, J.X. Zou, H.J. Kung, H.W. Chen, Androgen-induced recruitment of RNA polymerase II to a nuclear receptor-p160 coactivator complex, *Proc. Natl. Acad. Sci. USA* 100 (2003) 2226–2230.
- [19] T. Nakamura, Y. Imai, T. Matsumoto, S. Sato, K. Takeuchi, K. Igarashi, Y. Harada, Y. Azuma, A. Krust, Y. Yamamoto, H. Nishina, S. Takeda, H. Takayanagi, D. Metzger, J. Kanno, K. Takaoka, T.J. Martin, P. Chambon, S. Kato, Estrogen prevents bone loss via estrogen receptor alpha and induction of Fas ligand in osteoclasts, *Cell* 130 (2007) 811–823.
- [20] J. Kanno, K. Aisaki, K. Igarashi, N. Nakatsu, A. Ono, Y. Kodama, T. Nagao, "Per cell" normalization method for mRNA measurement by quantitative PCR and microarrays, *BMC Genomics* 7 (2006) 64.
- [21] W. Huang da, B.T. Sherman, R.A. Lempicki, Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources, *Nat. Protoc.* 4 (2009) 44–57.
- [22] Q.G. Ruan, K. Tung, D. Eisenman, Y. Setiady, S. Eckenrode, B. Yi, S. Purohit, W.P. Zheng, Y. Zhang, L. Peltonen, J.X. She, The autoimmune regulator directly controls the expression of genes critical for thymic epithelial function, *J. Immunol.* 178 (2007) 7173–7180.
- [23] P.G. Kumar, M. Laloraya, C.Y. Wang, Q.G. Ruan, A. Davoodi-Semiromi, K.J. Kao, J.X. She, The autoimmune regulator (AIRE) is a DNA-binding protein, *J. Biol. Chem.* 276 (2001) 41357–41364.
- [24] T. Org, F. Chignola, C. Hetenyi, M. Gaetani, A. Rebane, I. Liiv, U. Maran, L. Mollica, M.J. Bottomley, G. Musco, P. Peterson, The autoimmune regulator PHD finger binds to non-methylated histone H3K4 to activate gene expression, *EMBO Rep.* 9 (2008) 370–376.
- [25] D. Chen, M. Zhao, G.R. Mundy, Bone morphogenetic proteins, *Growth Factors* 22 (2004) 233–241.
- [26] T. Sakou, T. Onishi, T. Yamamoto, T. Nagamine, T.K. Sampath, P. Ten Dijke, Localization of smads, the TGF-beta family intracellular signaling components during endochondral ossification, *J. Bone Miner. Res.* 14 (1999) 1145–1152.
- [27] M. Zhao, M. Qiao, S.E. Harris, D. Chen, B.O. Oyajobi, G.R. Mundy, The zinc finger transcription factor Gli2 mediates bone morphogenetic protein 2 expression in osteoblasts in response to hedgehog signaling, *Mol. Cell. Biol.* 26 (2006) 6197–6208.
- [28] A.S. Koh, A.J. Kuo, S.Y. Park, P. Cheung, J. Abramson, D. Bua, D. Carney, S.E. Shoelson, O. Gozani, R.E. Kingston, C. Benoist, D. Mathis, Aire employs a histone-binding module to mediate immunological tolerance, linking chromatin regulation with organ-specific autoimmunity, *Proc. Natl. Acad. Sci. USA* 105 (2008) 15878–15883.
- [29] B. Shu, M. Zhang, R. Xie, M. Wang, H. Jin, W. Hou, D. Tang, S.E. Harris, Y. Mishina, R.J. O'Keefe, M.J. Hilton, Y. Wang, D. Chen, BMP2, but not BMP4, is crucial for chondrocyte proliferation and maturation during endochondral bone development, *J. Cell Sci.* 124 (2011) 3428–3440.
- [30] M. Harris, O. Kecha, C. Deal, C.R. Howlett, D. Deiss, V. Tobias, J. Simoneau-Roy, J. Walker, Reversible metaphyseal dysplasia, a novel bone phenotype, in two unrelated children with autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy: clinical and molecular studies, *J. Clin. Endocrinol. Metab.* 88 (2003) 4576–4585.
- [31] T. Yamada, H. Kawano, Y. Koshizuka, T. Fukuda, K. Yoshimura, S. Kamekura, T. Saito, T. Ikeda, Y. Kawasaki, Y. Azuma, S. Ikegawa, K. Hoshi, U.I. Chung, K. Nakamura, S. Kato, H. Kawaguchi, Carminerin contributes to chondrocyte calcification during endochondral ossification, *Nat. Med.* 12 (2006) 665–670.

Original Article

Oral administration of pentachlorophenol induces interferon signaling mRNAs in C57BL/6 male mouse liver

Jun Kanno¹, Ken-ichi Aisaki¹, Katsuhide Igarashi¹, Satoshi Kitajima¹, Nae Matsuda¹, Koichi Morita¹, Masaki Tsuji¹, Noriko Moriyama¹, Yusuke Furukawa¹, Maki Otsuka¹, Erika Tachihara¹, Noriyuki Nakatsu² and Yukio Kodama¹

¹Division of Cellular and Molecular Toxicology, Biological Safety Research Center, National Institute of Health Sciences, 1-18-1 Kamiyoga, Setagaya-ku, Tokyo 158-8501, Japan

²Toxicogenomics Informatics Project, National Institute of Biomedical Innovation, 7-6-8 Asagi Saito Ibaraki-City, Osaka 567-0085, Japan

(Received June 17, 2013; Accepted June 25, 2013)

ABSTRACT — Pentachlorophenol (PCP) was monitored for transcriptome responses in adult mouse liver at 2, 4, 8 and 24 hr after a single oral administration at four dose levels, 0, 10, 30 and 100 mg/kg. The expression data obtained using Affymetrix GeneChip MOE430 2.0 were absolutized by the Percellome method and expressed as three dimensional (3D) surface graphs with axes of time, dose and copy numbers of mRNA per cell. We developed the programs RSort, for comprehensive screening of the 3D surface data and PercellomeExploror for cross-referencing and confirmed the significant responses by visual inspection. In the first 8 hr, approximately 100 probe sets (PSs) related to PXR/SXR and Cyp2a4 and other metabolic enzymes were induced whereas Fos and JunB were suppressed. At 24 hr, about 1,200 PSs were strongly induced. We cross-referenced the Percellome database consisting of 111 chemicals on the liver transcriptome and found that about half of the PSs belonged to the metabolic pathways including Nrf2-mediated oxidative stress response networks shared with some of the 111 chemicals. The other half of the induced genes were interferon signaling network genes (ISG) and their induction was unique to PCP. Toll like receptors and other pattern recognition receptors, interferon regulatory factors and interferon alpha itself were included but inflammatory cytokines were not induced. In summary, these data indicated that functional symptoms of PCP treatment, such as hyperthermia and profuse sweating might be mediated by the ISG rather than the previously documented mitochondrial uncoupling mechanism. PCP might become a hint for developing low molecular weight orally available interferon mimetic drugs following imiquimod and RO4948191 as agonists of toll-like receptor and interferon receptor.

Key words: Pentachlorophenol, Mouse, Liver, Interferon signaling genes, Percellome toxicogenomics

INTRODUCTION

The Percellome Toxicogenomics Project is designed to identify dynamic and extensive networks of genes whose time- and dose-dependent patterns of expression in response to a chemical allows its toxic effects to be predicted. For this project, we developed a standardization method for microarrays and quantitative PCR that produces copy number of mRNAs per one cell (designated as "Percellome method") (Kanno *et al.*, 2006). This method allowed us to directly and quantitatively compare gene expression data among samples, studies, organs and even species using four arithmetic operations. One hundred

Correspondence: Jun Kanno (E-mail: kanno@nihs.go.jp)

and eleven chemicals (as of June 2013, Supplementary Table 1), most of which are known for their toxicity, were examined using the standard protocol of the project.

Pentachlorophenol (PCP) was examined in adult male C57BL/6 mouse liver. This compound has been used for multiple purposes such as herbicide, insecticide, fungicide, disinfectant, and other preservative purposes, moreover, its metabolism and toxicity, including carcinogenicity have been well studied. PCP is known to induce morphological changes in liver, kidney, hematopoietic, respiratory, immune and neural systems together with irritation of exposed sites. Hepatocarcinogenicity was demonstrated in rodents; the postulated mechanism involves

hydroxyl radical mediated DNA adduct formation and oxidative stress by the PCP metabolites. Functional symptoms, such as hyperthermia (sometimes life-threatening), profuse sweating, nausea, and uncoordinated movements were noted. Hyperthermia and other functional symptoms have been explained by the uncoupling of oxidative phosphorylation in mitochondria.

Here, we report that a comprehensive Percellome analysis revealed that PCP was the only chemical among the 111 tested in our project that strongly induced the interferon signaling gene (ISG) network. Additional pathways induced by PCP were Nrf2-mediated oxidative stress responses and other metabolic pathways more commonly seen among the 111 chemicals.

MATERIALS AND METHODS

Test chemical

PCP, standard grade (100.0% by gas chromatography coupled with flame ionization detector, Wako Pure Chemical Industries, Ltd., Tokyo, Japan) was dissolved in water containing 0.5% methyl cellulose (Shin-Etsu Chemical Co., Ltd., Tokyo, Japan).

Animal experiments

All experiments were carried out under approval of Experimental Animal Use Committee of National Institute of Health Sciences, Japan. C57BL/6 Cr Slc (Japan SLC, Inc., Shizuoka, Japan) twelve week-old male mice maintained in a barrier system with a 12 hr photoperiod were used in this study. Prior to the main study, a dose finding study was performed. This study revealed that 100 mg/kg was the maximum dose without clinical symptoms or alteration in H&E histology of the liver sampled 24 hr after single oral administration (a standard criteria for the top dose of the Percellome Project study). For the liver transcriptome experiments, forty eight mice were divided into four groups with twelve each, and given a single dose of PCP at 0, 10, 30 and 100 mg/kg by oral gavage. At 2, 4, 8 and 24 hr post-gavage, three randomly selected mice from each dose groups were euthanized by exsanguination under ether anesthesia and the livers were excised into ice-cooled plastic dishes. Tissue blocks weighing 30 to 60 mg were placed in an RNase-free 2 ml plastic tube (Eppendorf GmbH., Hamburg, Germany) and soaked in RNAlater (Ambion Inc., Austin, TX, USA) within 3 min of the beginning of anesthesia. The 12 animal sampling for each time point was finished within 25 to 30 min in order to avoid circadian-based variation within a time point.

Sample preparation and GeneChip measurement

The tissue blocks soaked in RNAlater were kept overnight at 4°C or until use. RNAlater was replaced in the 2 ml plastic tube with 1.0 ml of RLT buffer (Qiagen GmbH., Hilden, Germany), and the tissue was homogenized by adding a 5 mm diameter Zirconium bead (Funakoshi, Tokyo, Japan) and shaking with a MixerMill 300 (Qiagen GmbH) at a speed of 20Hz for 5 min (only the outermost row of the shaker box was used).

Three separate 10 μ l aliquots were taken from each sample homogenate to another tube and mixed thoroughly. A final 10 μ l aliquot there from was treated with DNase-free RNase A (Nippon Gene Inc., Tokyo, Japan) for 30 min at 37°C, followed by Proteinase K (Roche Diagnostics GmbH., Mannheim, Germany) for 3 hr at 55°C in 1.5 ml capped tubes. The aliquot was transferred to a 96-well black plate. PicoGreen fluorescent dye (Molecular Probes Inc., Eugene, OR, USA) was added to each well, shaken for 10 sec four times and then incubated for 2 min at 30°C. The DNA concentration was measured using a 96 well fluorescence plate reader with excitation at 485 nm and emission at 538 nm. λ phage DNA (PicoGreen Kit, Molecular Probes Inc.) was used as standard.

As reported previously, the graded-dose spike cocktail (GSC) made of the following five *Bacillus subtilis* RNA sequences were selected from the gene list of Affymetrix GeneChip arrays (AFFX-ThrX-3_at, AFFX-LysX-3_at, AFFX-PheX-3_at, AFFX-DapX-3_at, and AFFX-TrpX-3_at) present in the MOE430 arrays was added to the sample homogenates in proportion to their DNA concentrations (Kanno *et al.*, 2006). Then, the sample homogenates spiked with GSC were processed according to the Affymetrix standard protocol. The GeneChips used were Mouse 430 2.0. We used the in house developed SCA14 (Spike Calculation version 4, by K.A.) to check the efficiency of *in vitro* transcription, and the dose-response linearity of the five GSC spikes and to produce Percellome data, i.e. absolutized mRNA copy numbers of each PS were generated.

The data consist of four dose levels and four time points, generating a 4 x 4 matrix. The mean value (m) with standard deviation (sd) was calculated from the triplicates for all of the probe sets (PSs) for each dose-time points. In order to better visualize the changes at 2 hr, the vehicle value was used for putative zero point, and drawn a 5 x 4 surface three-dimension (3D) surface graph with X-axis for dose, Y for time, and Z for expression as shown in Fig. 1.




Fig. 1. Three dimensional surface expressions of Percellome Project data: The project data consist of four dose levels and four time points, generating 4 x 4 matrix. The mean value and standard deviation were calculated from the triplicate data. In order to better visualize the changes at 2 hr, the vehicle value was used for zero hour data to draw a 5 x 4 surface graph with X-axis for dose, Y for time, and Z for expression. Here, Affymetrix ID 1449851 at (Per1, period homolog 1) is shown. The 5 x 4 mesh made by the mean values was painted in translucent green (mean surface). The mean surface is rainbow-colored from blue, green, red to yellow according to its peak absolute values (cf. Fig. 3, Supplementary Fig. 1). Above and below the mean surface, +1sd and -1sd surfaces were overlaid using transparent blue. The dose-response curve at 2 hr, 4 hr, 8 hr and 24 hr are highlighted in blue, green, yellow and red. In a direction perpendicular to the dose-response curves, time course of each dose groups and vehicle group is indicated (not highlighted). The graph reads that the highest dose peaked at 4 hr at around 9 copies per cell; the middle dose peaked at 8 hr above 10 copies per cell. The vehicle group (V) showed the circadian change and peaked at 8 hr. The small red crosses are data of each animal sample (n = 3). Yellow asterisks indicate that the marked mean values were significantly different from concurrent vehicle value by $p < 0.05$ (Student's t-test).

Comprehensive selection of treatment-responding mRNAs

The in house developed software, RSort (Roughness Sort by K.A.) was used for automatic selection of treatment-responding mRNAs. This program sorts the PSs based on the roughness of the 3D surface. In other words, calculate the numbers of peaks (upward and downward) in a surface and sort by the number of peaks (maximum of eight peaks in 4 x 4 grid of the surface). Next, it fil-

ters the PSs by the number of peaks (normally three or less peaks) and additional parameters such as maximum expression level (normally more than one copy per cell for liver samples), p values between vehicle and top dose groups ($P < 0.05$ or $p < 0.01$). Here, a surface was selected when it had three peaks or less, the first peak in high doses (at any time) or the first peak in middle doses if its value is not significantly different from the neighboring high dose at $p < 0.01$ by Student's t-test, and the value of the peak is significantly different from that of vehicle control at $p < 0.05$ by Student's t-test. These automatically selected PSs were then visually checked for their 3D-surface shapes (to eliminate noisy data), and subdivided into those showed initial changes at 2, 4, 8, and 24 hr. A cross-referencing program named PE (Percellome Explorer, by K.A.) was used to select a list of chemicals that share PSs common to the visually confirmed list of PCP. The PE contains the gene lists automatically selected by the RSort of all data in our Percellome Project (168 datasets for liver samples, 286 for all samples), and automatically cross-refers and sorts out the chemicals sharing the same PSs (Fig. 2). The automatically selected gene lists (product sets) were visually checked to remove noise surfaces.

In Situ Hybridization

For *in situ* hybridization of Irf7 and Stat1 mRNAs, QuantiGeneViewRNA ISH Tissue Assay kit (Affymetrix, Inc., Santa Clara, CA, USA) was used. The probes were designed and synthesized by Affymetrix; regions covered were 2-1461 bases for Irf7 and 707-1710 bases for Stat1. 10% buffered formalin fixed liver tissues were dehydrated and embedded in paraffin. Tissue sections were mounted on "FRONTIER coated glass slides" (Matsunami Glass Ind., Ltd. Osaka, Japan). The slides were completely dried and stored until use. The slides were re-fixed in 10% formaldehyde for 1 hr at room temperature and washed with PBS and deparaffinized with xylene, pretreated in 1x Pretreatment Solution at 98°C for 30 min and digested with Protease QF at 40°C for 20 min. The probes were hybridized at 40°C for 2 hr and the signals were detected with Fast Red.

RESULTS

The numbers of PSs that started to change in response to PCP treatment at 2, 4, 8 and 24 hr were 98, 55, 127 and 1192 respectively (Supplementary Table 2, Supplementary Fig. 1). Chemicals or treatment in the Percellome database (Supplementary Table 1), that shared the PS list with PCP are shown in Table 1. The chemicals that shared the most with the 2 hr PS list of PCP




Fig. 2. PercellomeExplorer (PE) Software: The PE contains the gene lists automatically selected by the RSort software program of all data in our Percellome Project (168 datasets for liver samples, 286 for all samples, as of May 2013), and automatically picks up the chemicals sharing same PSs. TTG016-L(C), the study code for PCP, was selected from the upper window and the chemicals sharing the PSs were listed in the lower window. These lists await visual confirmation.

was sodium dihydroacetate (TTG154-L); 51 PSs, followed by acephate (TTG109-L); 24 PSs, down to 5-fluorouracil (TTG160-L); 4 PSs. The sum set (or union of sets in set theory) of the 2 hr PS lists that are listed in the 2 hr column of the Table 1 contained 75 PSs (up-regulated (Up) 59, down-regulated (D) 16). Likewise, the sum set of the 4 hr PS lists contained 31 PSs (Up 22, D 9), 8 hr 46 PSs (Up 23, D 23) and 24 hr 636 PSs (all Up). The PS list unique to PCP (Unique list) at each time point contained 23, 24, 81, and 556 PSs at each time points (cf. Supplementary Table 2).

Profiles of genes changed at 2, 4 and 8 hr

The PS list common to other chemicals (Common list) contained the gluconeogenesis pathway of PGC-1A (Pparg1a)/Foxo1/HNF4 (Puigserver *et al.*, 2003) that were induced at 2 hr (Fig. 3). This finding is in concordance with the report in experimental animals that PCP acutely induces hyperglycemia (Deichman *et al.*, 1942; Clayton and Clayton, 1981). Pparg1a was reported to increase the expression of Lpin1 (Finck *et al.*, 2006), which was also the case here. A small set of genes encoding metabolic enzymes was induced during the first 8 hr,

including Cyp2a4, Cyp4f16, Cyp7a1, Cyp17a1, Cyp39a1, Fmo2, and Fmo5 (Fig. 3).

Ingenuity pathway analysis (Ingenuity Systems, Inc. Redwood City, CA, USA) indicated that these genes are likely to be induced by Nr1i3 (CAR), Nr1i2 (PXR/SXR) or Nr5a1 (data not shown). Although our RSort program did not identify these nuclear receptors, manual search showed that PXR/SXR was induced by PCP (Fig. 3). These changes were not unique to PCP and shared by some of the chemicals in the Common list (cf. Supplementary Table 2).

Down regulation of Fos and JunB at 2, 4, and 8 hr (Fig. 3) was uniquely found in the PCP gene list. Bioinformatic analysis did not identify any associated pathways.

Profiles of genes started to change at 24 hr

The list of PSs induced at 24 hr contained two large networks. About half of the PSs showing altered expression by PCP were assigned to the interferon signaling pathway (Fig. 4, Supplementary Fig. 1). The interferon signaling genes (ISG) were highly up-regulated from Stat1, Stat2, Tyk, to Irf7, Myd88, Oas, Ifit, Cxcl10 and other downstream targets. Toll like receptors (TLRs) and

Table 1. The total numbers of probesets induced by PCP at each time points and those shared with other chemicals.

2 hr			4 hr			8 hr			24 hr		
Percollome No.	Treatment	PS	Percollome No.	Treatment	PS	Percollome No.	Treatment	PS	Percollome No.	Treatment	PS
TTG016-L(C)	Pentachlorophenol	98	TTG016-L(C)	Pentachlorophenol	55	TTG016-L(C)	Pentachlorophenol	127	TTG016-L(C)	Pentachlorophenol	1192
TTG154-L	Sodium Dehydroacetate	51	TTG104-L	MCHP	21	TTG098-L	DEHP	15	TTG098-L	DEHP	258
TTG109-L	Acephate	24	TTG098-L	DEHP	16	TTG041-L	Valproic Acid	14	TTG032-L	3-Amino-1H-1,2,4-triazole	212
TTG059-L	Caffeine	19	TTG037-L	Phenobarbital	14	TTG104-L	MCHP	14	TTG104-L	MCHP	177
TTG062-L(C)	Dexamethasone	18	TTG032-L	3-Amino-1H-1,2,4-triazole	12	TTG109-L	Acephate	13	TTG037-L	Phenobarbital	160
TTG041-L	Valproic Acid	18	TTG144-L	Erbavlin x Chlorzax	12	TTG160-L	5-fluorouracil	10	TTG041-L	Valproic Acid	109
TTG098-L	DEHP	17	TTG150-L	Valproic acid sodium salt x Thalidomide	8	TTG154-L	Sodium Dehydroacetate	9	TTG157-L	Valproic acid sodium salt	103
TTG019-L	2-Vinylpyridine	15	TTG141-L	Erbavlin x Chlorzax	8	TTG141-L	Erbavlin x Chlorzax	8	TTG031-L	2-Chloro-4-(3-dimethylamino)pyridine	94
TTG104-L	MCHP	12	TTG074-L	Dexamethasone	8	TTG031-L	2-Chloro-4-(3-dimethylamino)pyridine	8	TTG154-L	Sodium Dehydroacetate	77
TTG165-L	Chlorpyrifos	12	TTG151-L	Valproic acid sodium salt x Valproic acid sodium salt	7	TTG032-L	3-Amino-1H-1,2,4-triazole	8	TTG162-L	Valproic acid sodium salt	71
TTG034-L	4,4'-Dithiobis(6-tert-butyl-2-methylphenol)	12	TTG031-L	2-Chloro-4-(3-dimethylamino)pyridine	7	TTG146-L	Forskolin	6	TTG044-L	Chlorzax	69
TTG166-L	Carbaryl	10	TTG044-L	Chlorzax	6	TTG062-L(C)	Dexamethasone	6	TTG074-L	Phenobarbital	47
TTG031-L	1-Chloro-4-(3-dimethylamino)pyridine	10	TTG162-L	Valproic acid sodium salt	5	TTG054-L	Diethylnitrosamine (C57BL/6)	5	TTG109-L	Acephate	17
TTG141-L	Erbavlin x Chlorzax	9				TTG132-L	Curcumin	3	TTG160-L	5-fluorouracil	13
TTG032-L	3-Amino-1H-1,2,4-triazole	9				TTG136-L	Phytol	2			
TTG027-L	1,2,4-Triazole	9									
TTG160-L	5-fluorouracil	4									
	Sum Set (common)	75		Sum Set (common)	31		Sum Set (common)	46		Sum Set (common)	636
	Sum Set (Up)	59		Sum Set (Up)	22		Sum Set (Up)	23		Sum Set (Up)	636
	Sum Set (Dn)	16		Sum Set (Dn)	9		Sum Set (Dn)	23		Sum Set (Dn)	0
	PCP NOT Sum (unique to PCP)	23		PCP NOT Sum (unique to PCP)	24		PCP NOT Sum (unique to PCP)	81		PCP NOT Sum (unique to PCP)	556

Pentachlorophenol turns on interferon network in mouse liver




Fig. 3. Representative surface data of PSs induced at 2, 4 and 8 hr after PCP single gavage: Ppargc1a and Foxo1 are the members of gluconeogenesis pathway. A small set of genes of metabolic enzymes, such as Cyp2a4, Cyp4f16, Cyp7a1, Cyp17a1, Cyp39a1, Fmo2, and Fmo5 are induced during the first 8 hr. Nr1i2 or PXR/SXR is also induced. Down regulation of JunB and Fos at 2, 4, and 8 hr are noted. The graphs marked with (Inverted) are plotted with inverted z-axis, zero on top for better indication of suppression. The graphs with (Inverted, subtracted) are plotted, in addition to inverted z-axis, with the 2, 4, 8 and 24 hr values compensated by concurrent vehicle values so that the vehicle line is straight and cancels out the circadian changes.

other pattern recognition receptors (PRR), interferon regulatory factors (Irf) and interferon (Ifn) itself were included. These ISGs were uniquely induced by PCP. It is notable that inflammatory cytokines such as Tnf- α , IL-12 and CD40 were not effectively induced by PCP. The Ingenuity Pathways also plotted many genes in the interferon sig-

naling with a very high probability score (Fig. 6).

In situ hybridization confirmed that hepatocytes were producing the Irf7 and Stat1 in a dose dependent manner (Fig. 7, only vehicle and top dose were shown).

The other half was assigned, by Ingenuity Pathway analysis, to Nrf2-mediated Oxidative Stress Responses




Fig. 4. Surface data of ISGs: Among about 1,200 PSs induced at 24 hr, half of them were uniquely induced by PCP and were assigned to ISG pathway from Stat1, Stat2, Tyk, to Irf7, Myd88, Oas, Ifit, Cxcl10 and other downstream targets. Some Tlrs were also uniquely up-regulated (cf. Supplementary Table 2).

Pentachlorophenol turns on interferon network in mouse liver




Fig. 5. Surface data of Nrf2-mediated oxidative stress response genes: Among about 1,200 PSs induced at 24 hr, another half of them were Nrf2-mediated oxidative stress response genes commonly induced by PCP and other 10 or so chemicals (cf. Supplementary Table 2). Nrf2 itself did not alter but Keap1 was clearly induced.

J. Kanno et al.

Pentachlorophenol turns on interferon network in mouse liver




Fig. 6. Venn diagram of the PSs of PCP and sum set of other chemicals in Percellome Database. The PS list unique to PCP was assigned to Interferon signaling and related networks. The PSs induced by PCP and were shared by other chemicals in Percellome database were enriched in Nrf2-mediated oxidative stress response and Protein ubiquitination pathways. The names of the responses and their probability scores are generated by the Ingenuity Pathway analysis.




Fig. 7. *In situ* hybridization of Irf7 and Stat1. a) Vehicle control liver stained for Irf7. In a very low back ground, a small nest of hepatocytes was positively stained for Irf7. b) Vehicle control liver stained for Stat1. In a very low back ground, a small nest of hepatocytes was positively stained for Irf7. It is likely that the same hepatocyte is producing both mRNAs. c, d) High dose group stained for Irf7 and Stat1. Hepatocytes were shown to produce both mRNAs in a ubiquitous manner.




Fig. 8. Tentative summary scheme of the PCP induced networks in mouse liver. PCP or its metabolites may stimulate PXR/SXR or CAR, thereby inducing Cyp2, 4, 7, Fmo2, 5 within 8 hr to facilitate PCP metabolism, generating HQ (TCoHQ, TCpHQ), BQ (TCpBQ) and hydroxyl radical. The metabolites/radicals induce DNA damage and Protein damage. These reaction triggers Nrf2 networks and PRR system, initiating Irf mediated synthesis of Interferon alpha, which triggers the interferon signaling networks by autocrine or paracrine mechanisms. On the other hand, there remains a possibility that the metabolites may act as direct ligands to Tlr or IfnR and trigger downstream events as indicated in dotted lines with “?”. Before activating interferon signaling networks, PCP suppressed Fos and JunB, which might have suppressed the inflammatory cytokine induction as shown in dotted line with “?”.

accompanying distinct induction of Keap1, and other metabolic pathways (Figs. 5 and 6, Supplementary Table 1). Those networks were in the Common list mentioned above. Other networks were not effectively identified by the Ingenuity pathway analysis.

DISCUSSION

Among the chemicals tested in the Percellome project, PCP was slow to induce changes in gene expression; only around one hundred PSs were induced before 8 hr and 1,200 PSs at 24 hr. It would be plausible to hypothesize that PCP was metabolized during the first 8 hr and that the metabolite(s) then induced the 24 hr burst of ISGs and Nrf2-mediated genes. The time course of PCP action is in accord with the reported biological half-life of PCP; 6 to 27 hr in rodents (Larsen *et al.*, 1972; Braun *et al.*, 1977). A few metabolizing enzymes located downstream of PXR/SXR were induced during the first 8 hr

(Fig. 3). The presence of DEHP in the top part of the common chemical list in Table 1 is also consistent with this hypothesis.

It would be of interest to ascertain whether PCP or its metabolite(s) could be PXR/SXR ligands. Metabolites known are tetrachloro-p(o)-hydroquinone (TCpHQ and TCoHQ) and tetrachloro-p-benzoquinone (chloranil, TCpBQ). Further, TCpHQ is reported to be metabolized, generating hydroxyl radicals with a help of H₂O₂ without Fenton reaction, to trichloro-hydroperoxyl-1,4-benzoquinone (TrCBQ-OOH) and trichloro-hydroxy-1,4-benzoquinone (TrCBQ-OH) (Zhu and Shan, 2009). We have no Percellome data of those metabolites and, to date, there are no reports on the interaction of PCP or its metabolites with the PXR/SXR. There are reports that PCP affects the function of estrogen receptor (Jung *et al.*, 2004) and thyroid hormone receptor (Kawaguchi *et al.*, 2008). Further study will be needed to identify the triggering event for the earliest responses to PCP.

Hepatocarcinogenic activity of PCP has been shown by rodent studies (NTP, 1999). The metabolites of PCP mentioned above were considered as the cause of oxidative stress or the hydroxyl radical insults against the liver (Zhu and Shan, 2009; Tasaki *et al.*, 2012).

It was reported that Tlr4-mediated, lipopolysaccharide-induced activation of the *Ifn- β* promoter was inhibited by PCP in a Myd88-independent way (Ohnishi *et al.*, 2008). On the other hand, PCP was considered to trigger Tlr4 via the induction of hydroxyl radicals (Lucas and Maes, 2013). In our experiment, PCP had significantly up-regulated Myd88, Irak1, Traf6, Tlr2, Tlr3, Tlr5, Tlr9 at 24 hr. Although the induction did not reach statistical significance, Tlr4 expression was also elevated. In addition, Irf3, Irf7 and Irf9 were also induced. These findings might indicate that the TLR system was triggered by PCP itself, its metabolites or hydroxyl radicals via modifying the cytoplasmic proteins; abnormal proteins might be sensed by the TLRs or the pattern recognition receptors (PRR) system. Since Irf3, 7, 9 and *Ifn- α* 1 expression are also increased, it could be possible that Irf mediated autocrine or paracrine of the *Ifn- α* is triggered, resulting in a burst of ISGs, as postulated by Sato *et al.* (Sato *et al.*, 2000).

Although Myd88 is mobilized, NF- κ B, TNF, IL12 and CD40 were not induced, indicating that there may be a switch towards inflammatory cytokine production that was not directly induced by PCP. In relation to the switching mechanism, there is a report that isopropanol impaired AP-1 activation by removing Fos and JunB from the nuclear region of monocytes *in vitro* and suppressed Tlr4-mediated lipopolysaccharide stimulated Tnf- α production (Carignan *et al.*, 2011). In our data, Fos/JunB was down-regulated at earlier phase. As this change might correspond to AP-1 suppression (Gomard *et al.*, 2010), one possibility could be that PCP itself (as an alcohol/phenol) inhibited inflammatory cytokine production.

In contrast to the possible indirect mechanisms noted above, there are two examples that lead us to consider a possibility of direct activation of the ISGs. The first example is a low-molecular weight compound "imiquimod", a Tlr7 agonist, already on the market for treatment of skin viral infection (Hemmi *et al.*, 2002). Subcutaneous injection of imiquimod was reported to induce fever, sickness behavior and induction of ISG in rats (Damm *et al.*, 2012). The second example is a new polyfluoromethylated compound, 8-(1, 3,4-oxadiazol-2-yl)-2, 4-bis (trifluoromethyl) imidazo [1, 2-a] [1, 8] naphthyridine (RO4948191) which was reported to be an orally available low molecular weight interferon receptor agonist. RO4948191 was shown to induce a set of ISGs (Konishi *et al.*, 2012), such as *Oas1*, *Adar*, *Bst1*, *Stat1*, *Ifit3*, *Usp18*,

Isg15, *Herc6* and *Cxcl10*. These two examples of direct ligands to TLR and IFNR lead us to hypothesize that PCP and/or its metabolites may be able to directly activate these receptor systems (Fig. 8). Further investigation will be needed to clarify the molecular mechanism(s) through which PCP administration triggers the ISGs. It is tempting to speculate that this classic toxin, PCP, could be used as a new lead for orally applicable interferon-manipulating and/or cytokine switching drugs.

Hyperthermia or hyperpyrexia, profuse sweating, uncoordinated movement, muscle twitching, and coma are reported in humans and experimental animals as acute symptoms of PCP poisoning. These functional symptoms were reported to be caused by the mitochondrial uncoupling effect of PCP. *Ucp2* and *Ucp3* and some mitochondrial genes are induced in this study (Supplementary Table 2, Supplementary Fig 1). These genes are supportive for uncoupling effect. However, many of the Krebs cycle enzymes were not induced and those that were induced showed very small increases compared to the induction of ISGs. Some peroxidases were also mildly induced, but catalase was not induced by PCP. In the Percellome database, chemicals reported as uncouplers are aspirin, ethanol, sodium arsenite, and 2,4-dinitrophenol. Under the current computational condition, none of them was picked up as a chemical sharing PS list with PCP.

Taken together, our data may be interpreted to indicate that the functional symptoms represented by hyperthermia can be induced by PCP mainly through the activation of ISGs. This interpretation is backed up by the literature on "endogenous pyrogens" (Dinarello, 1999) and on imiquimod (Damm *et al.*, 2012).

Finally, although not yet perfected, the performance of the RSort and PE programs were demonstrated to be sufficient to sort out biologically meaningful changes for the comprehensive characterization of PCP. Manual searches employing different criteria added about 100 mildly changing PSs (data not shown), but the conclusions of our study were not affected. Nevertheless, further refinement for the better coverage is underway.

In conclusion, the RSort program-based comprehensive cross-reference of the Percellome database revealed that PCP was the only chemical among 111 orally administered chemicals that significantly induced the ISGs in hepatocytes. *In situ* hybridization confirmed that the parenchymal hepatocytes are responding to PCP. Two possible mechanisms were discussed; indirect mechanism via the PRR system, and direct stimulation of the Tlr(s) or IfnR(s). Further study is needed to clarify the possible molecular mechanisms.